Some of the leading pharma executives increasingly see AI as not only a tool for lead identification, but also a more general tool to boost biology research and identify new biological targets and develop novel disease models. The main focus of AI research for today is still on small molecules as a therapeutic modality.
Some of the leading pharma executives increasingly see AI as not only a tool for lead identification, but also a more general tool to boost biology
research and identify new biological targets and develop novel disease
models. The main focus of AI research for today is still on small molecules as a therapeutic modality.